Ratings by William Blair (Myles R. Minter)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/27/2024 | Alto Neuroscience | ANRO | New Coverage | Outperform (N/A) |
15.31 (13.57) |
-11.37% | Details | |
| 10/10/2023 | Neumora Therapeutics | NMRA | New Coverage | Outperform (N/A) |
11.94 (10.96) |
-8.21% | Details | |
| 7/24/2023 | Arcturus Therapeutics | ARCT | New Coverage | Outperform (N/A) |
33.84 (30.13) |
-10.96% | Details | |
| 12/15/2020 | Prevail Therapeutics | PRVL | Downgrade | Market Perform (Outperform) |
12.50 (23.00) |
84% | Details | |
| 5/29/2020 | Minerva Neurosciences | NERV | Downgrade | Market Perform (Outperform) |
13.47 (2.50) |
-81.44% | Details |
